Berovent

Berovent is a selective agonist acting on β-2-adrenoreceptors. It is used to eliminate obstructive respiratory pathologies.

Indications Beroventa

It is used for symptomatic therapy in acute asthmatic attacks. It is also prescribed for the prevention of asthma caused by physical activity.

It is used in symptomatic procedures aimed at eliminating bronchial asthma, whether of allergic or non-allergic origin, or other conditions in which curable obstruction of the respiratory tract is observed (for example, chronic obstructive bronchitis, with or without emphysema).

During long-term treatment, it is necessary to carry out an anti-inflammatory therapeutic course in addition to the main regimen.

Release form

The product is released as a metered inhalation aerosol, in a metal canister equipped with a spray nozzle and a protective cap, with a capacity of 15 ml (300 servings). The package contains 1 such canister.

Pharmacodynamics

Berovent has a pronounced bronchodilator effect, which develops due to stimulation of β2-adrenoreceptors of the bronchi. Bronchodilator properties are provided by the ability of the drug to stimulate adenylate cyclase, resulting in the accumulation of cAMP inside the cells. The latter component, affecting the activity of protein kinase, inhibits the ability of the substance myosin to be synthesized with actin, due to which there is a slowdown in smooth muscle contraction, helping to relax the bronchi.

Medicinal doses of the drug do not affect the functioning of vital organs, and do not have a local irritating effect. Use in large doses leads to loss of selectivity of action and development of stimulation of β1-adrenoreceptors.

The synthesis of drugs with β2-adrenoreceptors by stimulating the activity of Gs-protein activates the action of adenylate cyclase.

An increase in cAMP values activates the activity of protein kinase A, resulting in the phosphorylation of target proteins located inside smooth muscle cells. This effect causes phosphorylation of the kinase in the region of light myosin chains, suppression of phosphoinositide hydrolysis processes, and the opening of large K channels that are dependent on the Ca element.

Pharmacokinetics

After inhalation, the spread of the bronchodilator effect begins after a few minutes and then continues for 3-5 hours. The method of inhalation and the type of inhaler used determine the exact amount of the active element entering the lower part of the respiratory system (indicators fluctuate within 10-30%). The remainder of the drug settles in the upper part of the respiratory tract and in the mouth. Some of the drug is swallowed and enters the gastrointestinal tract.

After the first injection of Berovent, approximately 17% of the drug is absorbed. Absorption occurs in 2 stages - first, rapid absorption of 30% of fenoterol (with an absorption half-life of 11 minutes), and then slow absorption of 70% of the substance (the absorption half-life is 2 hours).

Dosing and administration

One aerosol spray contains 100-200 mcg of fenoterol hydrobromide. It is necessary to perform 2-3 inhalation procedures per day. If there is no result after the first inhalation procedure, it is allowed to repeat it after 5 minutes. In the future, inhalations must be performed at intervals of 5 hours.

To prevent the development of an asthma attack, it is often sufficient to administer 1 dose of the drug via inhalation.

To prevent the development of bronchial asthma due to physical exertion, 1-2 servings are used per inhalation (the maximum permissible limit of use per day is 8 servings – 1.6 mg of fenoterol).

During therapy in children, the drug is used in a dosage of 100 mcg, under the supervision of a physician or an adult.

[ 1 ]

Use Beroventa during pregnancy

Fenoterol crosses the placenta.

Berovent may only be used during pregnancy or breastfeeding after a comprehensive assessment of the benefits and risks (especially during the first trimester).

There is no information about the negative impact of fenoterol on infants. Since this element passes into mother's milk, the drug can be used during lactation only after the likely benefit and possible risks have been balanced.

There is no information on the effect of fenoterol hydrobromide on female fertility. Preclinical tests of this element have shown no negative effect on this function.

Contraindications

Main contraindications:

• the presence of hypersensitivity to fenoterol hydrobromide or inactive components of the drug;
• hypertrophic form of obstructive cardiomyopathy;
• tachyarrhythmia;
• It is prohibited to use this form of release in children under 4 years of age.

Side effects Beroventa

The use of the aerosol may cause the appearance of certain side effects:

• dizziness with headaches, feeling of strong excitability, arrhythmia and tachycardia;
• muscle tremors, cramps, myalgia, feeling of weakness;
• paradoxical bronchial spasms, cough, hyperhidrosis;
• vomiting with nausea;
• skin manifestations of allergies and itching;
• hypokalemia, as well as a decrease in diastolic pressure and an increase in systolic pressure values.

Overdose

Intoxication manifests itself as a feeling of anxiety, tachycardia, hand tremors, arrhythmia, angina attacks, skin hyperemia, and also a decrease in blood pressure. Incurable bronchial obstruction may also develop.

In the form of an antidote, drugs are used that block the action of β-adrenergic receptors (mainly of a cardioselective nature, because there is a risk of developing bronchial spasm), as well as tranquilizers and sedatives.

Interactions with other drugs

Xanthine derivatives, β-adrenergic drugs, and also anticholinergics may enhance the bronchodilator properties and side effects of Berovent.

β-agonist-induced hypokalemia may be enhanced when combined with xanthine derivatives, diuretics and steroids.

The incidence of arrhythmia in individuals taking the drug together with digoxin increases.

A decrease in the effectiveness of the drug may develop when used with β-blockers.

Tricyclics, MAOIs and halogenated hydrocarbons (used in inhalation anesthesia) can potentiate the development of negative cardiovascular effects.

[ 2 ]

Storage conditions

Berovent should be kept in a place out of reach of small children. The temperature level should not exceed 25°C.

Shelf life

Berovent can be used for 2 years from the date of release of the drug.